Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Keisuke Shikata"'
Autor:
Takuma Ohmichi, Takashi Kasai, Tadashi Kosaka, Keisuke Shikata, Harutsugu Tatebe, Ryotaro Ishii, Makiko Shinomoto, Toshiki Mizuno, Takahiko Tokuda
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0201260 (2018)
Caffeine has been considered a neuroprotective agent against Parkinson's disease (PD). Recent metabolomic analysis showed that levels of caffeine and its metabolites were decreased in sera from patients with PD compared with those from healthy contro
Externí odkaz:
https://doaj.org/article/7ad5a8ce83cf4e10aebb3bf9a0860d0b
Autor:
Yusuke Tabuchi, Masayuki Tsujimoto, Kosuke Yamamoto, Tadashi Kosaka, Koichi Sakaguchi, Naoya Dobuchi, Kohshi Nishiguchi, Keisuke Shikata
Publikováno v:
Cancer chemotherapy and pharmacology.
Pertuzumab (Per) is a humanized monoclonal antibody used in combination with trastuzumab (Tra) in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. The administration of biologics, such as Tra and Per, frequentl
Autor:
Yusuke Tabuchi, Masayuki Tsujimoto, Kosuke Yamamoto, Tadashi Kosaka, Koichi Sakaguchi, Naoya Dobuchi, Kohshi Nishiguchi, Keisuke Shikata
Purpose Pertuzumab (Per) is a humanized monoclonal antibody used in combination with trastuzumab (Tra) in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. The administration of biologics, such as Tra and Per, f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45c519f1f113729d93a672852a44ef3c
https://doi.org/10.21203/rs.3.rs-1730087/v1
https://doi.org/10.21203/rs.3.rs-1730087/v1
Autor:
Yusuke Tabuchi, Masayuki Tsujimoto, Kosuke Yamamoto, Tadashi Kosaka, Koichi Sakaguchi, Naoya Dobuchi, Kohshi Nishiguchi, Keisuke Shikata
Purpose: Pertuzumab (Per) is a humanized monoclonal antibody used in combination with trastuzumab (Tra) in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. The administration of biologics, such as Tra and Per,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bfe97054458291b159e35629ddaebf5
https://doi.org/10.21203/rs.3.rs-1294435/v1
https://doi.org/10.21203/rs.3.rs-1294435/v1
Autor:
Rei Murakami, Eiichiro Kanda, Yusuke Tabuchi, Yoshitaka Kato, Kanji Tomogane, Takahiro Mizoguchi, Arisa Miki, Yuichi Muraki, Yusuke Noguchi, Tomohiko Ejima, Keisuke Shikata, Shinji Sawada
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 46:22-30
Autor:
Tetsuya Taguchi, Motohiro Kanazawa, Norihiko Ihara, Rumi Kawano, Keisuke Shikata, Takeshi Ishikawa, Yuki Nakajima, Koichi Takayama, Tomoko Yoshioka, Toyoshi Hosokawa, Yuko Kanbayashi, Yusuke Tabuchi
Publikováno v:
Medical Oncology. 35
Although pegfilgrastim prophylaxis is expected to maintain the relative dose intensity (RDI) of chemotherapy and improve safety, information is limited. However, the optimal selection of patients eligible for pegfilgrastim prophylaxis is an important
Autor:
Harutsugu Tatebe, Takahiko Tokuda, Tadashi Kosaka, Ryotaro Ishii, Toshiki Mizuno, Takashi Kasai, Makiko Shinomoto, Takuma Ohmichi, Keisuke Shikata
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0201260 (2018)
PLoS ONE
PLoS ONE
Caffeine has been considered a neuroprotective agent against Parkinson’s disease (PD). Recent metabolomic analysis showed that levels of caffeine and its metabolites were decreased in sera from patients with PD compared with those from healthy cont
Autor:
Kosaka T, Yamada Y, Kimura T, Kodama M, Fujitomo Y, Masaki N, Toshiaki K, Keisuke S, Fujita N
Publikováno v:
The Japanese journal of antibiotics [Jpn J Antibiot] 2016 Feb; Vol. 69 (1), pp. 27-40.